Articles related to WOMEN'S HEALTH

This study randomly assigned participants to receive daily, low-dose antibiotic prophylaxis (n=120) or methenamine hippurate (n=120) for 12 months. Treatment allocation was not masked, and crossover between arms was permitted. The primary clinical outcome measure was the incidence of symptomatic, antibiotic-treated UTI episodes reported by participants over the treatment period. The urinary antiseptic methenamine hippurate was found to be noninferior to prophylactic antibiotics in preventing urinary tract infections (UTIs) in women who had them repeatedly. Results were published March 9 by The British Medical Journal (BMJ).